Trial Profile
An Open-label, Non-randomized, Multicenter Phase I Study to Determine the Maximum Tolerated or Recommended Phase II Dose of Oral Mutant IDH1 Inhibitor BAY1436032 and to Characterize Its Safety, Tolerability, Pharmacokinetics and Preliminary Pharmacodynamic and Anti-tumor Activity in Patients With IDH1-R132X-mutant Advanced Solid Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 10 Aug 2023
Price :
$35
*
At a glance
- Drugs BAY 1436032 (Primary)
- Indications Astrocytoma; Cholangiocarcinoma; Chondrosarcoma; Glioblastoma; Glioma; Oligodendroglioma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Bayer
- 06 Aug 2023 Planned End Date changed from 29 Dec 2023 to 31 Dec 2024.
- 01 Aug 2022 Planned End Date changed from 31 Dec 2022 to 29 Dec 2023.
- 23 Jul 2021 Planned End Date changed from 31 Dec 2021 to 31 Dec 2022.